CN100496623C - Heterogenic deproteinized osseous stent material and its preparation method - Google Patents
Heterogenic deproteinized osseous stent material and its preparation method Download PDFInfo
- Publication number
- CN100496623C CN100496623C CNB2006100543573A CN200610054357A CN100496623C CN 100496623 C CN100496623 C CN 100496623C CN B2006100543573 A CNB2006100543573 A CN B2006100543573A CN 200610054357 A CN200610054357 A CN 200610054357A CN 100496623 C CN100496623 C CN 100496623C
- Authority
- CN
- China
- Prior art keywords
- bone
- hours
- cell
- osseous
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000463 material Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title description 11
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 135
- 238000000034 method Methods 0.000 claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 210000001519 tissue Anatomy 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 2
- 239000012154 double-distilled water Substances 0.000 claims 2
- 235000015277 pork Nutrition 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 abstract description 5
- 230000007547 defect Effects 0.000 abstract description 2
- 230000003544 deproteinization Effects 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 30
- 230000000694 effects Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 238000007654 immersion Methods 0.000 description 11
- 239000007943 implant Substances 0.000 description 11
- 210000002536 stromal cell Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000011010 flushing procedure Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 238000002513 implantation Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229920002994 synthetic fiber Polymers 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019713 millet Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000002138 osteoinductive effect Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 231100000456 subacute toxicity Toxicity 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000002407 tissue scaffold Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000003275 diaphysis Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
本发明涉及骨支架材料，特别是涉及一种用于修复各种原因引起的骨缺损的异种骨支架材料，本发明进一步涉及制备所说的骨支架材料的方法。本发明的骨支架材料基本上没有免疫原性，但保留有良好的机械强度和力学性能。The present invention relates to a bone scaffold material, in particular to a heterogeneous bone scaffold material for repairing bone defects caused by various reasons, and further relates to a method for preparing said bone scaffold material. The bone scaffold material of the present invention basically has no immunogenicity, but retains good mechanical strength and mechanical properties.
Description
Technical field
The present invention relates to bone holder material, particularly relate to and be used to repair damaged bone tissue engineering scaffold of bone that a variety of causes causes and preparation method thereof.
Background technology
Along with field of tissue engineering technology bone defect repair progress of research, can bone holder material becomes the restriction tissue engineered bone really be applied to a clinical key factor.At present, to the selection of bone tissue engineer medium-height trestle material (the Boyan Bo that still disagrees, Lonmann CH, Romero J, Schwartz Z, Bone and cartilagetissue engineering, Clin Plast Surg, 1999,26 (4): 629-645.), the timbering material that is applied to bone tissue engineer is of a great variety, and Chinese scholars has been made many good tries (Burg KJ, Porter S, Kellam JF.Biomaterials developments for bone tissue engineering.Biomaterials, 2000,21 (23): 2347-2359.Karabuda C, Ozdemir O, Tosun T, et al.Histological andclinical evaluation of 3 different grafting materials for sinus lifting procedure basedon 8 cases.J Periodontol, 2001,72 (10): 1436-1442.).Ideal bone tissue engineering stent material should possess excellent biological compatibility, degradability, three-dimensional hole one grid structure of reasonable three-dimensional, plasticity and characteristics (Burg KJ such as certain mechanical strength and good cell one material interface, Porter S, KellamJF.Biomaterials developments for bone tissue engineering.Biomaterials, 2000,21 (23): 2347-2359).Used timbering material has two classes in the current bone tissue engineer research: (1) bio-derived material, as, lyophilizing decalcification bone, deproteinization bone and collagen etc.; (2) synthetic material is as polylactic acid, polyglycolic acid and poly-phosphazo etc.Adopt the natural bone holder material of deriving of different physics and chemistry technology preparations to compare with chemical synthetic material, material is after defat, decalcification, deproteinization etc. are handled, removed lipid and impurity albumen, reduced the antigenicity of material, and the natural mesh system of material is not damaged with retardation.This natural structure is beneficial to the adhesion and the growth of seed cell, and provide roomy surface area and inner space for the secretion of extracellular matrix, has favorable tissue affinity and adhesion (Mendes SC Tibbe JM, Veenhof M, et al.Bone Tissue Engineered Implants Using Human Bone MarrowStromal Cells:Effect of Cluture Conditions and Donor Age.Tissue Engineering, 2002,8 (6): 911-919; Orban JM, Marra KG, Hollinger J.Composition Options of TissueEngineered Bone.Tissue Engineering, 2002,8 (4): 529-536).Because there is high homology in bone structure between the different genera animal, bio-derived bone is easy to be discerned and substitute by host cell after implanting, show favorable biological degradability, material source is abundant, simple for production, and physicochemical property, histocompatibility, biological degradability and function adaptability aspect are better than synthetic material.
Discovering in the past, complete deproteinization bone, as Oswestry bone, Anorganic bone etc., though eliminated antigenicity basically, mechanical strength relatively poor relatively (Valentini P, Abensur D, Densari D, etal.Histological evaluation of Bio-Oss in a 2-stage sinus floor elevation andimplantation procedure:a human case report.Clin Oral ImplantsRes, 1998,9 (1): 59-67).And part deproteinization bone, as the Kiel bone, though mechanical strength still can, have poor antigen, effect is undesirable.So in concrete processing technology, the inorganic and organic principle that xenogenesis bone deproteinization is handled is than most important.The acid-soluble protein of a lot of non-collagens has immunogenicity in the xenogenesis bone organic principle, removes insufficiently then to keep than strong antigen, but removes then material brittle of too much collagen protein, influences biomechanical strength.
Based on existing defective among the deproteinization preparation technology in the past, analyzed the relation between the reservation of immunogenic elimination and diaphysis mechanical strength all sidedly.On this basis, major tuneup of the present invention the processing method and the step of xenogenesis osseous tissue, make xenogenesis bone of the present invention both eliminate antigenicity, can possess good biomechanical strength and osteoinductive again, thereby make it better effect in the human body bone is repaired.
Summary of the invention
An object of the present invention is to provide a kind of xenogenesis deproteinization bone tissue engineering scaffold, making it to have (1) does not have or has only extremely low immunogenicity; (2) enough comprcssive strength and mechanical resistance are arranged; (3) have good bone conductibility and osteoinductive, (4) have good three dimensional structure and high porosity, thereby more help the implantation and the adhesion of cell; (5) can arbitrarily be processed into different shape and size as required, and after implantation, can keep attitude in the general form of regenerating tissues; (6) can be compound with biologic activity factors such as bone morphogenetic protein (BMP), transforming growth factor-β, induce osteogenesis effectively.
The inventor is on the basis of having scrutinized and analyzed existing xenogenesis bone holder material and production method thereof, ingenious employing has also been made up a series of organic solvents, enzyme preparation and other chemical reagent treatment process, and be used in combination known Soxhlet extractor, through a large amount of repeatedly experimentatioies, successfully prepared xenogenesis bone holder material of the present invention finally.We show that to the various physics of the heterogenic deproteinized osseous tissue of the present invention and the analysis result of chemistry it has all characteristics and superperformance that ideal bone tissue engineering stent material should possess.Particularly, the comparative test that we do with heterogenic deproteinized osseous tissue of the present invention and at present commercially available like product shows, of the present invention heterogenic deproteinized osseous aspect physics and chemistry such as biocompatibility, degradability, 3 D stereo hole and grid structure, plasticity and mechanical strength and biology performance all significantly better than prior art products (data not shown goes out) such as Oswestry bone, Anorganic bones.
Second purpose of the present invention provides a kind of method for preparing described xenogenesis deproteinization bone tissue engineering scaffold.
In order to obtain xenogenesis deproteinization bone tissue engineering scaffold of the present invention, at first fresh pig rib and bones of limbs are carried out pretreatment: remove whole soft tissues and bone marrow, saw or cut into the about 10mm of length, 20mm and 30mm respectively, the bone piece that width and thickness equate.Then, handle as follows successively:
At first, at normal temperatures, cutting or the good osseous tissue of saw are placed 20%H
2O
2The middle immersion 24 hours used ddH
2After O flushing (30 minutes) flushing, once more at 20%H
2O
2The middle immersion 24 hours.Use ddH
2After the O flushing (30 minutes), use sodium azide (5mmol/L) successively, contain NaOH (1N), 5% trypsin and the 20%H of 1%tritonX-100
2O
2Each soaked 12 hours, and used ddH after each immersion respectively
2O flushing 30 minutes.Then, use 1:1 methanol/chloroform mixture, absolute ether, ethylenediamine and soaked in absolute ethyl alcohol 24,12,24 and 24 hours more successively.And, all use ddH between each the immersion
2O flushing 30 minutes, but soaked in absolute ethyl alcohol should be used ddH after 24 hours
2O continues to soak 24 hours.To in 50 ℃ of baking ovens, dry through the osseous tissue of as above handling.At last, use
60C
O(25KGY) irradiation sterilization.
Wherein, 1:1 methanol/chloroform mixing immersion, absolute ether and ethylenediamine soaking step are finished in the soxhlet extractor.To take off the bone of egg and put into extraction tube, add 1:1 methanol/chloroform, absolute ether and ethylenediamine successively, 60-70 ℃ was heated respectively 24 hours, 12 hours and 24 hours in extractor, it is 10 times/hour that above-mentioned solution flows in extractor, with adipose cell or the tissue in abundant dissolving and the removal bone, suppress the activity of endogenous enzyme effectively.
Xenogenesis bone of the present invention derives from the animal body, and it is extensive, with low cost therefore to make it material source.Particularly because the material of animal origin has grid structure and the composition closely similar with people's extracellular matrix, so through simple degrease, go cell and albumen etc. to handle after, can obtain being directly used in clinical timbering material of the present invention.The inventor is on the basis of known technology, select and optimize reagent, the selection of various variable concentrations and establish necessary processing condition and equipment thereof, finally prepare the xenogenesis deproteinization bone tissue engineering scaffold that physics and chemistry and biological property and performance all are better than existing like product astoundingly.
Handle reagent such as the employed oxidant of osseous tissue, organic solvent, detergent, protease in the inventive method and be common agents well known in the art.These reagent wherein, hydrogen peroxide (H
2O
2) effect be to remove the bone internal protein, and make protein denaturation; 20% H
2O
2Can make the collagen protein degeneration in most of osseous tissue and bring into play normal physiological function, wherein collagen not only provides support and protective effect for cell, and with adhesion, growth, the phenotypic expression of cell substantial connection is arranged all; The effect of sodium azide is to make the osteocyte inactivation; TritonX-100 is used to destroy cell membrane lipid and fat egg for nonionic scale remover commonly used; Highly basic NaOH solution-treated is in order further to remove the specificity noncollagen protein; Trypsinization is intended to make the iuntercellular proteolysis, more to help the free of cell; Chloroform and methanol soak the adipose cell or the tissue that not only can dissolve and remove in the bone, and can suppress the activity of endogenous enzyme effectively; Ether is handled and is then further removed remaining adipose cell; The function of ethylenediamine is to remove conjugated proteins such as phosphoprotein, sialoprotein in the bone, and is last, is in order further to remove liposoluble substance and to absorb moisture content with soaked in absolute ethyl alcohol.
Though used agent treated osseous tissues such as more strong oxidizer, organic solvent, detergent, protease in the method for the present invention, but because the inventor is based on experience is arranged, on selection, processing time and the condition of reagent, all done many improvement, think that obtaining having the heterogenic deproteinized osseous stent material that is better than prior art provides prerequisite and necessary technical support.
Compare with the deproteinization technology of using in the past, because breaking conventional conception of the present invention, effective choice also has been used in combination the extraction reagent of various immersions and residual protein and cell etc., and be used in combination the soxhlet extractor where necessary.Therefore, under the prerequisite of not destroying intrinsic form of osseous tissue and substructure, successfully removed nearly all antigenic substance.Thereby both eliminated immunogenicity, remained with the heterogenic deproteinized osseous stent material of good and enough mechanical strength and performance again.And this has also embodied technological progress of the present invention just.
Description of drawings
Fig. 1 shows scanning electron microscope (SEM) photo of deproteinization bone of the present invention, and as seen the three-dimensional porous structure and the netted hole of former tissue scaffold design arranged.
Fig. 2 shows the infrared analysis collection of illustrative plates of deproteinization osseous tissue sample of the present invention.As seen 1400-1700cm
-1There is the vibration of collagen relative keys at the place.
Fig. 3 shows the infrared analysis collection of illustrative plates of undressed fresh bone tissue sample.Wherein at 2927cm
-1The place can be observed the stretching vibration of c h bond with a sharp peak.
Fig. 4 shows heterogenic deproteinized osseous tissue back 1 week of implantation by the inventive method preparation, and the part has based on the massive inflammatory cells infiltrated of lymphocyte and mononuclear cell (HE * 400).
Fig. 5 shows implantation 2 weeks of back, and the local inflammation cellular infiltration obviously reduces (HE * 400).
The specific embodiment
Following examples are intended to illustrate, rather than limit the present invention by any way.
One. preparation xenogenesis deproteinization bone tissue engineering scaffold
At first fresh pig rib and bones of limbs are carried out pretreatment; Remove whole soft tissues and bone marrow, saw or cut into the about 10mm of length, 20mm and 30mm respectively, the bone piece that width and thickness equate.Then, handle as follows successively:
At normal temperatures, cutting or the good osseous tissue of saw are placed 20%H
2O
2The middle immersion 24 hours used ddH
2After O flushing (30 minutes) flushing, once more at 20%H
2O
2The middle immersion 24 hours.Use ddH
2After the O flushing (30 minutes), use sodium azide (5mmol/L) successively, contain NaOH (1N), 5% trypsin and the 20%H of 1%tritonX-100
2O
2Each soaked 12 hours, and used ddH after each immersion respectively
2O flushing 30 minutes.Then, use 1:1 methanol/chloroform mixture, absolute ether, ethylenediamine and soaked in absolute ethyl alcohol 24,12,24 and 24 hours more successively.And, all use ddH between each the immersion
2O flushing 30 minutes, but soaked in absolute ethyl alcohol should be used ddH after 24 hours
2O continues to soak 24 hours.To in 50 ℃ of baking ovens, dry through the osseous tissue of as above handling.At last, use
60C
O(25KGY) irradiation sterilization promptly gets xenogenesis deproteinization tissue engineered bone support material.
1:1 methanol in the said method/chloroform mixing immersion, absolute ether and ethylenediamine soak to be finished in the soxhlet extractor.To take off the bone of egg and put into extraction tube, add 1:1 methanol/chloroform, absolute ether and ethylenediamine successively, 60-70 ℃ was heated respectively 24 hours, 12 hours and 24 hours in extractor, it is 10 times/hour that above-mentioned solution flows in extractor, with adipose cell or the tissue in abundant dissolving and the removal bone, suppress the activity of endogenous enzyme effectively.
Two. above-mentioned gained xenogenesis deproteinization tissue engineered bone support material is analyzed:
Embodiment 1: heterogenic deproteinized osseous analysis of physical and chemical property of the present invention
Heterogenic deproteinized osseous histology, scanning electron microscope, infrared spectrum, X-ray diffraction analysis, X heat input scattering analysis, micro-kjeldahl determination and the mechanics performance determining of carrying out to preparation.The result of these observations and experimental analysis is as described below.
1. reach histological observation substantially: the deproteinization bone that makes is white column (size about 10mm * 5mm * 3mm), the visible porous honeycomb structure of naked eyes, hard, the free from extraneous odour of quality.The HE demonstration of dyeing, the deproteinization trabecular bone structure is clear, and a matter and cell are sloughed, cortical bone flaggy shape structural integrity; And fresh bone visible between matter and cell.The deproteinization bone interstitial collagen stock-dye positive, the mucin stain feminine gender; And fresh bone organizes mucin and collagen staining all positive.
2. scanning electron microscope (SEM) is observed: as seen the deproteinization bone has the three-dimensional porous structure and the netted hole (referring to Fig. 1) of former tissue scaffold design, traffic mutually between the hole, and its porosity is 65.5% ± 6.45%, pore size is 472.5 ± 7.02 μ m.
3. infrared spectrum analysis: deproteinization bone of the present invention is at 1400-1700cm
-1There is the vibration of collagen relative keys at the place, shows exist (Fig. 2) that collagen is arranged.And fresh bone is at 2927cm
-1The stretching vibration that the place can be observed c h bond shows and contains a certain amount of fat (Fig. 3) in the bone with a sharp peak.
4.X x ray diffraction analysis x: the collection of illustrative plates of fresh bone and deproteinization bone is the shaped form hydroxyapatite, but fresh bone contains more amorphous component.
5.X ray energy scattering analysis: the Ca/P ratio of fresh bone is 1.71 ± 0.95, and the deproteinization bone is 1.68 ± 0.76, the two there was no significant difference (P〉0.05).
6. protein content determination: recording fresh bone amyloid proteins matter content with micro-Kjeldahl is 26.6 ± 2.23%, 19.1 ± 2.14% of deproteinization bone, the two significant difference (P＜0.01).
7. mechanics performance determining: the load-deflection curve of fresh bone and deproteinization bone is that function recording instrument is traced out the bone piece and cut lotus-deformation curve behind the stand under load, increase along with load, the bone piece is compressed, curve becomes non-linear change by linear relationship, and form first crest, promptly carrier changes little and is out of shape increase obviously.At this moment, visible bone piece has the little fine strain of millet fracture of part bone.When the time continue to form second crest, the littler fine strain of millet of boniness was compressed, destroy at last, the deproteinization bone except that elastic modelling quantity raises, there was no significant difference (referring to table 1) between compression failure load and limit of rupture load and the fresh bone.
The biomechanical strength of table 1 liang group material is (n=10) relatively
* compare P＜0.05 with fresh bone
Therefore as can be seen, deproteinization bone of the present invention has good mechanical intensity, mechanical resistance, and has good three dimensional structure and high porosity.
Embodiment 2: heterogenic deproteinized osseous bio-safety Journal of Sex Research of the present invention
Present embodiment is intended to adopt standard methods such as acute and sub-acute toxicity test, hemolytic test, pyrogenic test, intracutaneous test, muscle Implant experiment and cell toxicity test, estimates the biological safety after heterogenic deproteinized osseous the implanting of the present invention.These result of experiment of following brief description.
1. the test of acute and sub-acute toxicity: mice is in the observation period, and receptor mice appetite normal psyche is full, activity freely, untoward reaction such as apnea suppresses, rapid.The weight of animals obviously increases after 72 hours.Anatomic observation does not have ascites, the tolerant no adhesion of intraperitoneal, and organs such as HE dyeing demonstration liver,spleen,kidney there is no unusually.
2. hemolytic test: the lixiviating solution of deproteinization bone of the present invention is 2.82% (referring to table 2) to the Sanguis Leporis seu oryctolagi hemolysis rate
Table 2 hemolytic test result (oD value)
Annotate: the hemolytic index of deproteinization bone=(0.084-0.082)/(0.792-0.082) * 100%=2.82%
3. pyrogenic test: body temperature fluctuation and is not higher than body temperature before the injection before and after all laboratory animals injections after the injection in 0.8 ℃, and fluctuating margin is less than 1.4 ℃.
4. skin irritation test: each time point of injection back is observed and is shown, injection lixiviating solution and normal saline place find no erythema, edema or downright bad the appearance, inject behind the 20% ethanol normal saline 6 hours to 72 hours visible injection zone the erythema of 1.5-2.0cm diameter is arranged, the core edema is obvious, and erythema deepens and occur the core necrosis gradually to form a scab then.
5. muscle Implant experiment: implanting back 48 hours wounds has redness and inflammatory cell infiltration is arranged, 1 week the back wound healing.After implanting for 2 weeks, fibrous capsule begins to form, and back inflammatory cell minimizing, and visible multinucleated giant cell engulfs granule around the material.Do not see under the mirror muscular tissue degeneration, necrosis or the implant phenomenon (Fig. 4,5) of being ostracised is arranged
6. cell toxicity test: heterogenic deproteinized osseous cytotoxicity to the L929 cell is 0 grade (seeing Table 3), and there was no significant difference between cell proliferation rate and the negative control (P〉0.05) is with positive controls comparing difference significantly (P＜0.05).
Table 3 different materials is to the influence (OD value) of L929 cell
*: compare P＜0.05 with test group
Embodiment 3: heterogenic deproteinized osseous cytocompatibility Journal of Sex Research of the present invention
Present embodiment is described the result of heterogenic deproteinized osseous cytocompatibility Journal of Sex Research.
After heterogenic deproteinized osseous and the compound cultivation of marrow stromal cell of the present invention, adopt inverted phase contrast microscope and scanning electron microscopic observation adherent growth state, and with active survival rate, level of differentiation and vigor and the metaboilic level that detects in transplanted come out of judging cell of mtt assay, flow cytometer and alkali phosphatase (ALP).
1. inverted phase contrast microscope and histological observation
Deproteinization bone and marrow stromal cell meet to be cultivated after 24 hours, and cell all can adhere to and distribute in material surface and hole, along with the prolongation of incubation time, and cell further growth, differentiation and propagation.The compound cultivation of marrow stromal cell and material is after 7 days, and visible cell is adherent, gathering is agglomerating or connect into netted.HE dyeing showed cell is in the internal breeding of material hole and the substrate secretion is arranged.
2. scanning electron microscopic observation
Marrow stromal cell and material meet to be cultivated after 7 days, and cell all can adhere at material surface.Cell is fusiformis or polygon, has projection to interconnect between flanking cell, and cell peripheral has netted collagen to adhere to.
3.MTT method detects
Compare with the cell single culture, the compound cultivation of marrow stromal cell and material 1,3,5 and 7 days, the cell viability not statistically significant (P〉0.05).
Table 4 material is to the influence (n=4, mean ± standard deviation) of marrow stromal cell vigor
P>0.05
4. flow cytometer detects cell cycle
Compare with the separate cell cultivation, the compound cultivation of marrow stromal cell and material is after 7 days, and each is organized cell cycle and does not see significant change, no abnormality seen times somatic cell (referring to table 5).
Table 5 material is to the influence (n=4) of marrow stromal cell cycle and times body level
5. alkali phosphatase (ALP) active level detects
Along with the prolongation of incubation time, the compound cultivation of marrow stromal cell and material and two groups of cell APL of single culture activity all use increase, but the ALP level does not have significant difference (P〉0.05) between two groups of same time points.
Table 6 determination of alkaline phosphatase activity value (u/g protein, average ± standard deviation)
P>0.05
By the result of above observation and experimentation as can be seen, the heterogenic deproteinized osseous good cell compatibility that has really of the present invention.
Embodiment 4: heterogenic deproteinized osseous dystopy skeletonization research in the compound cells body of the present invention
Present embodiment uses of the present invention heterogenic deproteinized osseous as the marrow stromal cell timbering material, and research is implanted the heterogenous allosome animal body with it and is implanted into the influence of back to the receptor ossification.
Heterogenic deproteinized osseous and the marrow stromal cell of cultivating of the present invention after compound 1 week of cultivation, are implanted rabbit back intramuscular (experimental group), use the heterogenic deproteinized osseous implantation of conventional method preparation to organize in contrast simultaneously, carry out parallel comparative experiments.The 4th and 8 weeks after the implant surgery, implanted material is taken out in operation, carry out alkali phosphatase (ALP) content detection in perusal, conventional organization inspection, blood plasma and the tissue, so as to the skeletonization level of analysis and comparison implant surface, and then judge that heterogenic deproteinized osseous graft is to the influence to receptor ossification and osteanagenesis.
As seen specimen observes substantially, and in 4 and 8 weeks after the implant surgery, the embedded material surrounding soft tissue of each treated animal there is no phenomenons such as necrosis, suppuration, hydrops.But visible material has a large amount of fibrous tissue and blood vessel soft tissue parcel and grows into, and is difficult to separate.
2.ALP active the detection
Compared in 4 weeks with implanting the back, implant active obviously raise (P＜0.05) of plasma A LP of the experimental group animal after 8 weeks.And, to compare with matched group, the same time after implantation, the experimental group animal also shows higher ALP activity (P＜0.01) (referring to table 7).
Table 7 is respectively organized materials A LP determination of activity result (IU) (average ± standard deviation)
Implant 4 weeks of back, compare P＜0.05 with experimental group, compare with the matched group that detects mutually with a period of time
*P＜0.01
3. conventional organization is learned and is checked
In 4 weeks of postoperative, as seen experimental group has zona cartilaginea to form, and the osseous tissue of a small amount of calcification is wherein arranged, and visible on every side fusiformis mesenchymal cell breaks up to chondrocyte.In 8 weeks of postoperative, visible woven bone and pulp cavity form, and seeing in it has the island trabecular bone, the still visible chondrocyte of periphery.Do not see any cartilage or new bone formation in the matched group, with implanting time lengthening, and ecto-entads such as the muscular tissue around the visible material, fibrous tissue, blood vessel are grown in the material hole gradually.
4. skeletonization degree quantitative analysis
Use the skeletonization degree of conventional method evaluation experimental group implant.As seen the result is 4.78 ± 0.81 when being 2.89 ± 0.61,8 weeks during 4 weeks.And with the prolongation of the time of implantation, new bone more becomes ripe.
Embodiment 5: heterogenic deproteinized osseous immunology research of the present invention
The immunoreation that may cause after heterogenic deproteinized osseous the implanting of present embodiment research is for the clinical practice of xenogenesis osseous tissue of the present invention provides the immunology foundation.
Respectively will be by heterogenic deproteinized osseous, the thigh back flesh bag of implanting BALB/C mice from body bone and untreated fresh xenogenesis bone of the inventive method preparation.Then, respectively at postoperative the 1st, 2,4 and 6 weeks putting to death animal, observe cell, humoral immune reaction and the local organization reaction of transplanting the back mice.
The result:
1. LS proliferation experiment
After above-mentioned three kinds of no osseous tissues are implanted BALB/C mice, observe receptor each the time splenocyte put mutually breeder reaction when suffering corresponding implant stimulation (referring under tabulate 8).
Table 8 is implanted back external lymphocyte secondary stimulus propagation stimulation index (SI)
By the result shown in the table 8 as can be seen, after implanting for 1 week, fresh bone tissue lymph cells in vitro propagation stimulation index is apparently higher than the deproteinization bone and from body bone group (P＜0.01), after implanting 2 weeks of back, fresh bone tissue lymph cytositimulation index reached peak, and deproteinization bone and do not have obvious rising from body bone group, the SI value is starkly lower than fresh bone group (P＜0.01).
These results suggest, fresh bone have stronger immunogenicity, can stimulate body immune system after implanting, and cause tangible cellular immunization.Deproteinization bone of the present invention is then little to the lymphopoiesis influence, and antigenicity is faint.，
The serological specificity antibody horizontal detects: after each experimental group animal is implanted treated xenogenesis bone, shown in the following tabulation 9 of serological specificity antibody test result.
Table 9 is implanted back serum specific antibody (OD value)
The fresh bone group each the time put mutually and obviously be higher than deproteinization bone and from body bone group (P＜0.05)
By the data shown in the table 9 as can be seen, deproteinization bone of the present invention and from the body bone each the time OD value put mutually between unknown significance difference (P〉0.05).This result shows that deproteinization bone of the present invention is not induced obvious visible humoral immune reaction after implanting in the animal body.
Histological observation: after fresh bone is implanted, each the time put all visible partial massive inflammatory cells infiltrated mutually, promptly show tangible rejection; Although deproteinization bone of the present invention and have a small amount of neutrophilic leukocyte to ooze out at the implantation initial stage from the body bone, 2-4 soaks into vanished cell after week, and shows a large amount of fibrous tissue and grow into.This result shows that deproteinization bone of the present invention has the better tissues compatibility.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100543573A CN100496623C (en) | 2006-06-14 | 2006-06-14 | Heterogenic deproteinized osseous stent material and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100543573A CN100496623C (en) | 2006-06-14 | 2006-06-14 | Heterogenic deproteinized osseous stent material and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1861202A CN1861202A (en) | 2006-11-15 |
| CN100496623C true CN100496623C (en) | 2009-06-10 |
Family
ID=37388788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100543573A Expired - Fee Related CN100496623C (en) | 2006-06-14 | 2006-06-14 | Heterogenic deproteinized osseous stent material and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100496623C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111110918B (en) * | 2019-09-26 | 2020-08-21 | 中新棠国业(苏州)医疗科技有限公司 | Preparation method of high-strength implant-grade bone material |
| CN111494715B (en) * | 2020-04-17 | 2022-03-29 | 东南大学 | High-molecular bone filling material and preparation method thereof |
| CN114209883B (en) * | 2021-12-22 | 2022-08-23 | 天新福（北京）医疗器材股份有限公司 | Preparation method of heterogeneous bone repair material |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1304711A (en) * | 2000-12-15 | 2001-07-25 | 华西医科大学附属第一医院 | Bio-derivative tissue engineering bone and its preparing process |
| CN1463756A (en) * | 2002-06-06 | 2003-12-31 | 北京市创伤骨科研究所 | Method for preparation of artificial bone antigen for biological origin |
| CN1552467A (en) * | 2003-11-05 | 2004-12-08 | 中国人民解放军第三军医大学野战外科 | Abnormal decelled bone based material and its preparation |
-
2006
- 2006-06-14 CN CNB2006100543573A patent/CN100496623C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1304711A (en) * | 2000-12-15 | 2001-07-25 | 华西医科大学附属第一医院 | Bio-derivative tissue engineering bone and its preparing process |
| CN1463756A (en) * | 2002-06-06 | 2003-12-31 | 北京市创伤骨科研究所 | Method for preparation of artificial bone antigen for biological origin |
| CN1552467A (en) * | 2003-11-05 | 2004-12-08 | 中国人民解放军第三军医大学野战外科 | Abnormal decelled bone based material and its preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1861202A (en) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9642937B2 (en) | Preparation method for implantable medical biological materials of animal origin | |
| EP2968419B1 (en) | Molded placental tissue compositions and methods of making and using the same | |
| CN101020082B (en) | Bone repairing material and its prepn process and use | |
| CN107029296B (en) | Periosteum repairing piece for guiding bone regeneration, preparation method and application | |
| Sano et al. | Acellular adipose matrix as a natural scaffold for tissue engineering | |
| CN101496912B (en) | Bio-derivative tendon repair material and preparation method thereof | |
| CN109054047A (en) | A kind of silk gum/graphene oxide composite hydrogel and its preparation method and application | |
| CN101563450A (en) | Method for preparing a cell-derived extracellular matrix membrane | |
| US20240108661A1 (en) | Preparation method for decellularized matrix biomaterial | |
| CN100372511C (en) | Acellular dermal matrix | |
| WO2018120672A1 (en) | Bioactive stent for inducting regeneration of tendon tissue, preparation method therefor and use thereof | |
| CN104640577B (en) | The hydrophilic dehydration containing phosphate groups and partially purified skeleton displacement material | |
| Tran et al. | Preparation and characterization of acellular porcinepericardium for cardiovascular surgery | |
| CN101690829A (en) | Method for preparing re-cellularized biological valve material | |
| WO2020258828A1 (en) | Tissue-engineering bone scaffold and preparation method therefor | |
| CN107890586B (en) | Preparation method of allogeneic biological breast patch | |
| JP2023505966A (en) | Biomaterials for bone tissue engineering | |
| CN100496623C (en) | Heterogenic deproteinized osseous stent material and its preparation method | |
| CN105492034A (en) | Method for enzymatic treatment of tissue products | |
| CN116966344A (en) | Deer antler cancellous bone cell-free tissue engineering scaffold material and preparation method and application thereof | |
| Kumaresan et al. | Development of Human Umbilical cord based scaffold for tissue engineering application | |
| CN107224618A (en) | Promote active scaffold material, its preparation method and the application of osteanagenesis | |
| Remya et al. | Bone marrow derived cell-seeded extracellular matrix: A novel biomaterial in the field of wound management. | |
| Huh et al. | Rapid expansion and auto-grafting efficiency of porcine full skin expanded by a skin bioreactor ex vivo | |
| Fadeeva et al. | Study of Biointegration and Elastic-Strength Properties of a New Xenopericardium-Based Biomaterial for Reconstructive Cardiovascular Surgery. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090610 Termination date: 20130614 |